Compare GSK plc (GSK) vs Mondaycom Ltd (MNDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Mondaycom Ltd — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Mondaycom Ltd trades at $88.96 (market cap $3.76B). The key difference: GSK plc is far larger — about 24.4× Mondaycom Ltd's market cap, and GSK plc pays a 3.9% dividend while Mondaycom Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Mondaycom Ltd for 16 Days on average.
| GSK | MNDY | |
|---|---|---|
Market Cap | $91.88B | $3.76B |
Volume | 7,730,529 | 836,200 |
Sector | Health | Technology |
52-Week High | $61.18 | $205.24 |
52-Week Low | $43.24 | $58.81 |
Typical Hold Time | 93 Days | 16 Days |
Enterprise Value | $111.88B | $2.92B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
Monday.com (MNDY) trades at $88.96, up 6.53% in the last session, showing strong momentum after recent earnings beats. The stock maintains bullish technical signals with support at $86 and resistance at $90. Fundamentally, the company demonstrates robust revenue growth reaching $1.23 billion in 2025 with impressive 88.74% gross margins, though valuation multiples remain elevated with a P/E of 37.69. Recent news highlights the company's AI initiatives at its Elevate '26 conference and inclusion in multiple growth stock lists.
The outlook remains positive with Wall Street consensus at $108.64 target price and 65% buy ratings, though risks include competitive pressure from Meta's enterprise push and elevated valuation multiples. Earnings momentum continues with three consecutive quarterly beats, but investors should monitor the upcoming Q3 2026 results against $1.37 EPS expectations for continued validation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Mondaycom Ltd
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →
